CANF Quote Trading Chart Can-Fite Biopharma Ltd Sponsored...

$0.89 Last:

5.96% Change Percent:

$0.9 Open:

$0.83996 Previous Close:

$0.9 High:

$0.86 Low:

69,665 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2022-08-12	0.9	0.83996	0.9	0.86	69,665
2022-08-11	0.884	0.83996	0.8988	0.86	65,551
2022-08-10	0.86	0.83996	0.8799	0.8302	91,957
2022-08-09	0.88	0.83996	0.88	0.8402	50,560
2022-08-08	0.865	0.83996	0.88	0.834	84,165
2022-08-05	0.84	0.83996	0.865	0.84	21,995
2022-08-04	0.855	0.83996	0.8644	0.8402	52,967
2022-08-03	0.855	0.83996	0.86	0.8401	68,335
2022-08-02	0.85	0.83996	0.8906	0.83	29,875
2022-08-01	0.85	0.83996	0.85	0.8303	59,280
2022-07-29	0.816	0.83996	0.8495	0.8121	59,377
2022-07-28	0.83996	0.83996	0.8593	0.8	95,028
2022-07-26	0.8284	0.8284	0.8455	0.8099	20,973
2022-07-19	0.81	0.8225	0.8296	0.8	121,733
2022-07-18	0.81	0.8065	0.8367	0.801	136,871
2022-07-15	0.84	0.8079	0.84	0.781	177,535
2022-07-14	0.86	0.801	0.8987	0.8	353,307
2022-07-13	0.89	0.8701	0.89	0.87	70,957
2022-07-12	0.9261	0.88	0.9395	0.8	403,018
2022-07-11	0.9	1.01	1.03	0.9	871,542

Stock Information

Can-Fite Biopharma Ltd Sponsored ADR Company Name:

CANF Stock Symbol:

NYSE Market:

Get CANF Alerts

News, Short Squeeze, Breakout and More Instantly...

CANF - Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Further analysis of Phase III COMFORT ™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla ® Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company ...
CANF - Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT(TM) Study in Moderate to Severe Psoriasis

Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions...
CANF - Can-Fite's CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

CF602’s unique mechanism of action enables potential treatment of diabetic patients and may offer an alternative to PDE5 (Viagra, Cialis, Levitra, and Stendra) non-responders accounting for 30-35% of the $3.6 billion ED market Patents granted in numerous healthc...